Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma: a case report and literature review

J Gastrointest Cancer. 2011 Mar;42(1):57-60. doi: 10.1007/s12029-010-9147-y.

Abstract

Purpose: To introduce a case of primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma (ALCL) and discuss its diagnosis and treatment.

Methods: Esophagectomy was done for a 37-year-old male with a submucosal lesion after a frozen section failed to give a definite diagnosis. Samples were sent for hematoxylin-eosin staining and immunohistochemical analysis. Six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy were given and the patient was followed up.

Results: The operation was uneventful. Postoperative pathologic and immunohistochemical examination yielded a diagnosis of primary CD30-positive and ALK-positive ALCL of the esophagus. The patient was in complete remission at the 14-month follow-up.

Conclusions: ALCL of the esophagus should be considered in the differential diagnosis of esophageal submucosal lesions. Biopsy through either esophagoscopy or surgical exploration, chemotherapy, and radiotherapy can be chosen for long-term survival.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Esophageal Neoplasms / drug therapy
  • Esophageal Neoplasms / metabolism
  • Esophageal Neoplasms / pathology*
  • Humans
  • Immunoenzyme Techniques
  • Ki-1 Antigen / metabolism*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Lymphoma, Large-Cell, Anaplastic / metabolism
  • Lymphoma, Large-Cell, Anaplastic / pathology*
  • Male
  • Neoplasms, Multiple Primary / drug therapy
  • Neoplasms, Multiple Primary / metabolism
  • Neoplasms, Multiple Primary / pathology*
  • Prednisone / therapeutic use
  • Receptor Protein-Tyrosine Kinases / metabolism*
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Ki-1 Antigen
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
  • Prednisone

Supplementary concepts

  • CHOP protocol